# Cagrilintide vs Semaglutide: How They Differ | PepVault

Source: https://pepvault.app/peptides/compare/cagrilintide-vs-semaglutide

Last updated: 2026-10-06

[Library](https://pepvault.app/peptides) [Comparisons](https://pepvault.app/peptides/compare) Cagrilintide vs Semaglutide

Compared side by side

# Cagrilintide vs semaglutide: how they differ

Reviewed October 2026 [How we check the library](https://pepvault.app/about#library)

## The short answer

They act on different hormones: cagrilintide is a long-acting analogue of amylin, the fullness hormone the pancreas releases with insulin, and semaglutide is a GLP-1 receptor agonist. Semaglutide is FDA-approved; cagrilintide isn’t approved on its own, and it is the amylin half of Novo Nordisk’s CagriSema. Both are weekly shots.

## Side by side

| Compared | [Cagrilintide](https://pepvault.app/peptides/cagrilintide) | [Semaglutide](https://pepvault.app/peptides/semaglutide) |
| --- | --- | --- |
| Category | Metabolic & GLP-1 | Metabolic & GLP-1 |
| Also known as | Cagri, AM833, NNC0174-0833 | Ozempic, Wegovy |
| What it is | A long-acting version of amylin, the fullness hormone the pancreas releases alongside insulin, given as a weekly shot. | A GLP-1 receptor agonist that mimics a gut hormone your body releases after eating: it reduces appetite and slows stomach emptying. |
| How it works | Long-acting, lipidated analogue of amylin, the satiety hormone the pancreas releases with insulin. It activates amylin receptors and the calcitonin receptor (a non-selective amylin agonist); amylin promotes fullness, slows stomach emptying and holds back glucagon after meals. A fatty-acid chain stretches its half-life to about a week, so it is a weekly shot, usually run beside a GLP-1. Not approved on its own: it is the amylin half of Novo Nordisk's CagriSema. | GLP-1 receptor agonist that reduces appetite, slows gastric emptying, and improves glucose metabolism. FDA-approved for T2DM and obesity. Titrate dose slowly to minimize GI side effects. |
| Commonly reported | Feeling full sooner and portions shrinking, with nausea or constipation after step-ups and some injection-site reactions. It is not approved on its own. | The constant background thoughts about food ("food noise") go quiet and portions shrink without effort, with nausea worst in the first days after each dose step. FDA-approved for type 2 diabetes, weight management, heart-risk reduction and MASH, with about 15% average weight loss at 68 weeks in its main trial. |
| Studied range | Research range: 0.25–2.4 mg, starting dose 0.25 mg. Studied in research — not a recommendation. | FDA label: 0.25–2.4 mg, starting dose 0.25 mg. |
| How often | Weekly | Weekly SubQ |
| Half-life | ~1 week (measured in people: 159–195 hours in a phase 1b trial) | ~1 week (FDA label) |
| Route | SubQ injection | SubQ injection |
| Typical run | Trials run it continuously: 26 weeks in phase 2, 68 weeks in phase 3. Community use is mostly as a weekly add-on to a GLP-1. | FDA-approved for ongoing use. Community uses indefinitely or until goal weight reached, then tapers. |
| Evidence | Established: clinical trials or FDA-approved use exists | Established: clinical trials or FDA-approved use exists |
| Common side effects | Nausea, constipation, diarrhea, injection-site reactions | Nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, pancreatitis risk |

Typical run: Community practice — opinions vary. Not a clinical recommendation.

## Week by week

Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.

### Cagrilintide

- Day 1–28 · 0.25 mg The 0.25 mg start
- Day 29–364 · 0.5 mg 0.5 mg, the second step
- Day 57–364 · 1 mg 1 mg, the middle step
- Day 85–364 · 1.7 mg 1.7 mg, the step before 2.4 mg
- Day 113+ · 2.4 mg 2.4 mg, the phase 3 dose

[Every card for cagrilintide, with its sources](https://pepvault.app/peptides/cagrilintide#weeks)

### Semaglutide

- Day 1–28 · 0.25 mg Gut is adapting
- Day 29–56 · 0.5 mg Appetite shifts are real now
- Day 57–112 · 1 mg Clinically useful weight loss kicks in
- Day 113–140 · 1.7 mg Max submaximal step
- Day 141–364 · 2.4 mg Full dose — the working dose
- Day 365+ Plateau territory — new baseline

[Every card for semaglutide, with its sources](https://pepvault.app/peptides/semaglutide#weeks)

## Together or one or the other

Cagrilintide and semaglutide are a common stack: cagrilintide lists semaglutide among its common stacks.

The two in one regimen: [CagriSema](https://pepvault.app/peptides/cagrisema)

RCT · Cagrilintide

### With semaglutide: the CagriSema pair

This is the pairing with trial data. Together, as CagriSema, the two averaged 22.7% weight loss at 68 weeks for people who stayed on treatment, against 16.1% for semaglutide alone; in the trials both stepped up together every 4 weeks.

## Questions people ask

### How long do cagrilintide and semaglutide last?

The half-life of cagrilintide is ~1 week (measured in people: 159–195 hours in a phase 1b trial). The half-life of semaglutide is ~1 week (FDA label).

### How often are cagrilintide and semaglutide taken?

Cagrilintide: weekly. Route: SubQ injection. Semaglutide: weekly SubQ. Route: SubQ injection.

### How are cagrilintide and semaglutide dosed in research?

The research range for cagrilintide is 0.25–2.4 mg, with a 0.25 mg starting dose. Studied in research — not a recommendation. The FDA label range for semaglutide is 0.25–2.4 mg, with a 0.25 mg starting dose.

### What are the common side effects of cagrilintide and semaglutide?

For cagrilintide, the library lists: nausea, constipation, diarrhea, injection-site reactions. For semaglutide: nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, pancreatitis risk.

### Are cagrilintide and semaglutide taken together?

Cagrilintide and semaglutide are a common stack: cagrilintide lists semaglutide among its common stacks. This is the pairing with trial data. Together, as CagriSema, the two averaged 22.7% weight loss at 68 weeks for people who stayed on treatment, against 16.1% for semaglutide alone; in the trials both stepped up together every 4 weeks.

## Each one in full

- [Cagrilintide: dosage, half-life & reference guide](https://pepvault.app/peptides/cagrilintide)
- [Semaglutide: dosage, half-life & reference guide](https://pepvault.app/peptides/semaglutide)
- [Cagrilintide dose guide](https://pepvault.app/lab/dosage/cagrilintide)
- [Semaglutide dose guide](https://pepvault.app/lab/dosage/semaglutide)

PepVault for iPhone

## Track either one in PepVault

Log every dose of cagrilintide or semaglutide, with reminders on your schedule. 7 days free on the yearly plan for new subscribers.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=compound-vs-band&mt=8)

[Explore the live demo](https://pepvault.app/login)

## More comparisons

- [All peptide comparisons](https://pepvault.app/peptides/compare)
- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)
- [Retatrutide vs Semaglutide](https://pepvault.app/peptides/compare/retatrutide-vs-semaglutide)
- [Orforglipron vs Semaglutide](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide)
- [Liraglutide vs Semaglutide](https://pepvault.app/peptides/compare/liraglutide-vs-semaglutide)
- [Retatrutide vs Tirzepatide](https://pepvault.app/peptides/compare/retatrutide-vs-tirzepatide)
- [Mazdutide vs Tirzepatide](https://pepvault.app/peptides/compare/mazdutide-vs-tirzepatide)

## The library

- [The peptide reference library](https://pepvault.app/peptides)
- [Metabolic & GLP-1 peptides](https://pepvault.app/peptides#metabolic)

## Free tools

- [The Dose Guide](https://pepvault.app/lab/dosage)
- [Half-life & active level](https://pepvault.app/tools/peptide-half-life-calculator)
- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it. Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Saxenda, Victoza and Trulicity are trademarks of their respective owners; PepVault is independent and not affiliated with or endorsed by any manufacturer.

© 2026 PepVault